Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia
Australian & New Zealand Journal of Psychiatry May 26, 2026 Yash Giri, Paul Furst, Colleen K Loo et al. 1 citation
Novel treatments for treatment-resistant depression, such as ketamine, esketamine, transcranial magnetic stimulation, and psilocybin-assisted therapy, are available in Australia but mostly through commercial clinics that require out-of-pocket payment, leaving many patients without access. The authors identify barriers including difficulty diagnosing treatment-resistant depression, lack of clinician training, and regulatory and economic hurdles. They propose establishing specialist treatment-resistant depression clinics, particularly in the public sector, to improve access and build expertise.